Name: Bacterial Infectious Diseases Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: PH2790
Price: 4350 USD
Availability: InStock

Bacterial Infectious Diseases Therapeutics Market Size Growth & Forecast 2023-30

Bacterial Infectious Diseases Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Bacterial Infectious Diseases Therapeutics Market is segmented&nbsp;By Disease Type (Bacterial Skin Infections, Foodborne Bacterial Infections, Sexually Transmitted Bacterial Infections, Others),&nbsp;By Therapeutics (Beta-Lactam, Quinolones, Macrolides, Tetracyclines, Sulfonamide, Others),&nbsp;By Route of Administration (Oral, Topical, Parenteral, Others),&nbsp;By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

Bacterial Infectious Diseases Therapeutics Market was valued at USD 75.8 billion in 2021. It is forecasted to reach USD million by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).&nbsp;Bacterial infectious diseases are infectious diseases occurred due to bacteria that trigger a protective immune response. It involves the proliferation of a harmful strain of bacteria on or inside the body. Bacteria are the single-celled microorganisms found in all sorts of environments, including soil, water bodies, and in or on other bodies. Bacteria are present in different shapes including rod-shaped (bacilli), spherical (cocci), or helical (spirilla). Bacterial infectious diseases can affect the throat, lungs, skin, bowel and other body parts. Bacterial infectious diseases are characterized by various signs and symptoms including bloody urine, frequent urination, diarrhea, fatigue, fever, sore throat, headache, cough, aches, nausea, vomiting, rashes, lesions, abscesses, weakness, and others. Bacterial infectious diseases increase the risk of causing life-threatening complications, such as blood poisoning, kidney failure, toxic shock syndrome, and others.

As per DataM Intelligence, Bacterial Infectious Diseases Therapeutics Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Bacterial Infectious Diseases Therapeutics Market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Bacterial Infectious Diseases Therapeutics Market in the United States and Canada produces the utmost share. Whereas the European Bacterial Infectious Diseases Therapeutics Market is projected to continue its presence globally during the period of 2022- 2029.

<h3>Bacterial Infectious Diseases Therapeutics Market Report Scope:</h3>

<table border="1" cellpadding="1" cellspacing="1">
	<tbody>
		<tr>
			<td>
			<h3>Metrics</h3>
			</td>
			<td>
			<h3>Details</h3>
			</td>
		</tr>
		<tr>
			<td>
			<h3>CAGR</h3>
			</td>
			<td>
			<h3>8.2%</h3>
			</td>
		</tr>
		<tr>
			<td>
			<h3>Segments Covered</h3>
			</td>
			<td>
			<h3>By Disease Type,&nbsp;By Therapeutics,&nbsp;By Route of Administration,&nbsp;By Distributional Channels, and By Region</h3>
			</td>
		</tr>
		<tr>
			<td>
			<h3>Report Insights Covered</h3>
			</td>
			<td>
			<h3>Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.</h3>
			</td>
		</tr>
		<tr>
			<td>
			<h3>Regions Analyzed</h3>
			</td>
			<td>
			<h3>North America, Latin America, Europe, Middle East, Africa, Asia Pacific, and the Rest of the world.</h3>
			</td>
		</tr>
		<tr>
			<td>
			<h3>Major Companies Covered</h3>
			</td>
			<td>
			<h3>Abbott Laboratories, EKF Diagnostics Holdings plc, BioM&eacute;rieux SA, Atlas Medical, Quidel Corporation, BIOSYNEX SA, Prestige Brands Holdings, Swiss Precision Diagnostics (SPD) GmbH, Piramal Enterprises, NG BIOTECH SAS, and among the major companies listed in the final report.</h3>
			</td>
		</tr>
	</tbody>
</table>

To know more insights into the Diagnostic Imaging Market, get our <a href="https://www.datamintelligence.com/download-sample/bacterial-infectious-diseases-therapeutics-market">Sample Brochure</a>

Market Dynamics

Growing Older Population is Driving the Growth of the Market

The demand for bacterial infectious diseases therapeutics is increasing with the rising older population as the older population is at a high risk of developing bacterial infectious diseases. Severe bacterial infectious diseases are observed among the older population due to several factors such as medical conditions, weakened immune system, concurrent use of different drugs, delayed diagnosis, delayed or diminished response to therapy.

According to the United Nations (UN) report, the older population of age-group 65 years or above was 727 million worldwide in 2020. The older population is expected to be more than double and reach up to 1.5 billion in 2050. Asia has a higher older population in comparison to Europe and Northern America. Urinary tract infections, skin infections, gastrointestinal infections, pneumonia, influenza, and others are most frequent among the older population.

Increasing Antibacterial Resistance is Expected to Boost the Development of Therapeutics over the Forecast Period.

There is growing antibacterial resistance due to the emergence and spread of drug-resistant pathogens. According to the World Health Organization (WHO)&rsquo;s new Global Antimicrobial Surveillance System (GLASS), antibiotic resistance was observed among 500,000 people with suspected bacterial infections across 22 countries. Approximately, 86% of new TB cases in &nbsp;30 high &nbsp;TB burden countries in 2020.

Several factors such as misuse and overuse of antibacterial, lack of access to clean water, sanitation and hygiene (WASH), poor infection and disease prevention and control in healthcare facilities, poor access to quality, affordable medicines, vaccines and diagnostics, lack of awareness and knowledge, and lack of enforcement of legislation are causing the antibacterial resistance. The antibacterial resistance is limiting the treatment of the most frequent bacterial infectious diseases. There is a rising spread of multi- and pan-resistant bacteria infections not being treatable by using the existing antibacterial worldwide. The increasing antibacterial resistance has resulted in the rising development of therapeutics for the treatment of bacterial infectious diseases. The pipeline of bacterial infectious diseases is robust with the involvement of several therapeutics being developed. Several companies are developing therapeutics that is effective in overcoming the resistance demonstrated by existing antibacterial. According to the World Health Organization (WHO), there are approximately 32 antibiotics in clinical development that address the WHO list of priority pathogens. Out of these 32 antibiotics in the pipeline, only six were classified as innovative.

Rising Organizations &amp; Institutes Initiatives for Overcoming the Antibacterial Resistance is Fueling the Market Growth

Several organizations &amp; institutes have raised initiatives for overcoming antibacterial resistance. For instance, The India government has launched a &ldquo;National Programme on AMR Containment during the 12th five-year plan, which is coordinated by NCDC. This phased manner included 35 state medical college labs and 26 states/UT. World Health Organization (WHO) had entered into the Global Antibiotic Research and Development Partnership (GARDP) with the Drugs for Neglected Diseases Initiative (DNDi). This partnership aims at developing and delivering the five new treatments that target drug-resistant bacteria identified by WHO as posing the greatest threat by 2025.

The United States Food and Drug Administration (FDA) has passed the Generating Antibiotic Incentives Now (GAIN) act for addressing the public health threat of antibacterial drug resistance by stimulating the development and approval of new antibacterial and antifungal drugs.

COVID-19 Impact Analysis

The bacterial infectious diseases therapeutics has witnessed drastic growth with the increasing number of people suffering from the COVID-19 as the antibacterial are being used for the treatment of bacterial infections among the patients with COVID-19. Various bacteria species such as Staphylococcus spp., Enterococcus spp., Klebsiella pneumonia, Enterobacter spp., Escherichia coli, Acinetobacter spp., and Pseudomonas spp are causing the infection among the patients with COVID-19.

According to the Bradley J. Langford et.al., 2020 study published in clinical microbiology &amp; infection (CMI), bacterial co-infection was observed among 3.5% of COVID-19 patients and 14.3% of COVID-19 patients. Approximately, 71.9% of COVID-19 patients received antibiotics for the treatment of bacterial infections.&nbsp; Antibiotics such as azithromycin, ceftriaxone, quercetin, rapamycin, doxycycline, and other antibiotics are mostly recommended among the patients. Azithromycin has demonstrated the anti-inflammatory effects that can be useful for reducing an overactive immune response to COVID-19.

Epidemiology

According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, the estimation that the prevalence of Rheumatoid Arthritis (RA) was resulted in 3.26 million in 2019. Women are two to three times as likely to be affected in comparison to men. It has been observed that around one in 12 women and one in 20 men would develop an inflammatory autoimmune rheumatic disease during their life. According to Giegerich E et.al. 2018, the diagnosed prevalence of Crohn&rsquo;s Disease was 6 cases per 100,000 in lower-income Asia-Pacific, 46 cases per 100,000 in high-income Asia-Pacific, 133 cases per 100,000 in Europe, and 210 cases per 100,000 in North America in 2017. The diagnosed prevalence of Crohn&rsquo;s Disease is highest among people of age-group 40-54 years. The prevalence of ankylosing spondylitis was observed to be 23.8 per 10,000 in Europe, 16.7 per 10,000 in Asia, 31.9 10,000 in North America, 10.2 10,000 in Latin America and 7.4 per 10,000 in Africa.

Segment Analysis

Beta-Lactam segment is expected to hold the largest share in the Bacterial Infectious Diseases Therapeutics market

By therapeutics, the market is classified as beta-lactam, quinolones, macrolides, tetracyclines, sulfonamide, and others. The Beta-lactam segment is anticipated to hold the largest share as it is the most prescribed antibacterial for the prevention &amp; treatment of bacterial infection. The beta-lactam acts by inhibiting cell wall synthesis. It targets the penicillin-binding proteins (PBPs) involved in the cross-linking of the bacterial cell wall. &beta;-Lactam antibiotics are effective against a broad range of clinical indications. Penicillin&rsquo;s, cephalosporins, carbapenems, and monobactams are the beta-lactam antibacterial with the highest market penetration.

There is increasing research and development activities for beta-lactam therapeutics. For instance, in March 2019, Iterum Therapeutics had received Qualified Infectious Disease Product (QIDP) and Fast Track Designations from the United States Food and Drug Administration (FDA) for its oral and intravenous (IV) formulations of sulopenem in four new indications including the community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory disease. Sulopenem had also received the Qualified Infectious Disease Product (QIDP) and Fast Track Designations for the treatment of uncomplicated urinary tract infection (uUTI), complicated urinary tract infection (cUTI), and complicated intra-abdominal infection (cIAI).

By Distribution Channel, Retail Pharmacies Segment is Expected to Witness a High Growth Over the Forecast Period

The market is classified on the distribution channel as the hospital pharmacies, retail pharmacies, online pharmacies and others. The retail pharmacies are segmented to have the highest market growth due to the high availability of therapeutics for the treatment of bacterial infectious diseases in the retail pharmacies &amp; drug stores. There is an increase in the number of retail stores across the globe. According to the cross-sectional survey, approximately 93.5% of antibiotics including amoxicillin and trimethoprim-sulfamethoxazole were prescribed by the majority of the registered drug shops.

Geographical Analysis

North America region holds the largest market share global Bacterial Infectious Diseases Therapeutics market

North America region is dominating the global bacterial infectious diseases therapeutics market accounted for the largest market share in 2021 owing to the increasing prevalence of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the incidence cases of tuberculosis was 7,860 in the United States in 2021. The total number of incidence cases of salmonella and Lyme disease was 58,371 and 34,945 respectively in the United States in 2019. There is a growing prevalence of antibacterial resistant infections. According to the Centers for Disease Control and Prevention (CDC), every year more than 2.8 million people were affected by antibiotic-resistant infections 2019. Every year more than 35,000 people died due to antibiotic-resistant infections.

The United States accounts for the highest market share due to the higher usage of therapeutics for the treatment of bacterial infectious diseases. According to the Centers for Disease Control and Prevention (CDC), the healthcare providers had prescribed 270.2 million antibiotic prescriptions i.e., 836 antibiotic prescriptions per 1000 persons. There is rising approval &amp; launch of therapeutics for the treatment of bacterial infectious diseases. For instance, on 4th June 2020, the United States Food and Drug Administration approved Recarbrio. The Recarbrio is to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in patients 18 years of age and older. The easy availabilities of the antibacterial shall stimulate the market growth over the forecasted period.

Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period 

Asia-Pacific region is estimated to be the fastest-growing region in the global bacterial infectious disease therapeutics market owing to the increasing prevalence of bacterial infectious diseases with the increasing older population. According to the United Nations Report, there were around 87millions of the population of age-group 65 years or over in India. The increasing investment for the improvement of the healthcare facilities &amp; infrastructure shall have a positive impact on the market.

There is increasing research and development activities for the development of therapeutics for the treatment of bacterial infectious diseases. There is a presence of several market players developing therapeutics for the treatment of bacterial infectious diseases. There is growing awareness regarding the use of antibacterial for the treatment of bacterial infection. The increasing domestic income and purchasing power of people shall boost the demand for bacterial infectious diseases therapeutics over the forecasted period.

Competitive Landscape:

The bacterial infectious diseases therapeutics market studied is a fragmented market with the presence of a large number of market players. Novartis AG, GlaxoSmithkline Plc, Pfizer Inc, Merck &amp; Co., Inc., Sanofi, Allergan, Bayer AG, AstraZeneca Plc, Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson and Johnson, and Teva Pharmaceuticals Industries Ltd. are the major market players with the significant market share. Companies are adopting several growth strategies such as product approvals, product launches, acquisitions, mergers, collaborations, and licensing for increasing their market presence. For instance,

Mergers &amp; Collaborations:

In July 2019, Nosopharm had entered into the collaboration with Evotec SE for advancing the NOSO-502, a novel antibiotic class against Enterobacteriace infections to the clinical stage of development and develop a second-generation Odilorhabdin for the treatment of hospital-acquired pneumonia and ventilation-associated pneumonia (HAP/VAP)

Product Launch &amp; Approvals:

In July 2019, Merck &amp; Co. had received approval from the United States Food and Drug Administration (FDA) for the Recarbrio (imipenem, cilastatin, and relebactam) injection, 1.25 grams, a new combination antibacterial. Recarbrio is recommended for the patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms such as Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumonia, and Pseudomonas aeruginosa.

In July 2019, Merck &amp; Co. had received the approval for Zerbaxa (ceftolozane and tazobactam) from the United States Food and Drug Administration (FDA) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years and older.

Allergan plc had received the approval to expand the use of Avycaz (ceftazidime and avibactam) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by the following susceptible Gram-negative microorganisms including the Klebsiella pneumoniae, Enterobacter cloacae, Escherichia coli, Serratia marcescens, Proteus mirabilis, Pseudomonas aeruginosa, and Haemophilus influenza in patients 18 years of age or older.

On 19th August 2019, The United States Food and Drug Administration approved Xenleta to treat adults with community-acquired bacterial pneumonia. This new drug provides a better option for treating patients with community-acquired bacterial pneumonia.

Acquisition: 

In February 2020, Grifols had acquired the Aradigm, an antibiotic developer.

On 11th October 2021, Sandoz completed the acquisition of GSK&rsquo;s cephalosporin business, confirming Sandoz&#39;s commitment to the antibiotics business.

<h3 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Trending Topics</h3>

<a href="https://www.datamintelligence.com/research-report/respiratory-infectious-disease-diagnostics-market">Respiratory Infectious Disease Diagnostics Market</a>

<a href="https://www.datamintelligence.com/research-report/infection-control-market">Infection Control Market</a>

<h3>&nbsp;</h3>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">Table of Content</h2>

<ol>
	<li>
	Methodology and Scope

	<ol>
		<li>
		Research Methodology
		</li>
		<li>
		Research Objective and Scope of the Report
		</li>
	</ol>
	</li>
	<li>
	Market Definition and Overview
	</li>
	<li>
	Executive Summary

	<ol>
		<li>
		Market Snippet by Disease Type
		</li>
		<li>
		Market Snippet by Therapeutics
		</li>
		<li>
		Market Snippet by Route of Administration
		</li>
		<li>
		Market Snippet by Distribution Channel
		</li>
		<li>
		Market Snippet by Region
		</li>
	</ol>
	</li>
	<li>
	Market Dynamics

	<ol>
		<li>
		Market Impacting Factors

		<ol>
			<li>
			Drivers

			<ol>
				<li>
				Growing Older Population
				</li>
				<li>
				Increasing Prevalence of Bacterial Infectious Diseases
				</li>
				<li>
				XX
				</li>
			</ol>
			</li>
			<li>
			Restraints

			<ol>
				<li>
				Adverse Effects of Therapeutics
				</li>
				<li>
				Genetic Mutations
				</li>
				<li>
				XX
				</li>
			</ol>
			</li>
			<li>
			Opportunity
			</li>
			<li>
			Impact Analysis
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Industry Analysis

	<ol>
		<li>
		Porter&#39;s Five Forces Analysis
		</li>
		<li>
		Epidemiology
		</li>
		<li>
		Pipeline Analysis
		</li>
		<li>
		Supply Chain Analysis
		</li>
		<li>
		Pricing Analysis
		</li>
		<li>
		Regulatory Analysis
		</li>
		<li>
		Reimbursement Analysis
		</li>
		<li>
		Unmet Needs
		</li>
	</ol>
	</li>
	<li>
	COVID-19 Analysis

	<ol>
		<li>
		Analysis of Covid-19 on the Market

		<ol>
			<li>
			Before COVID-19 Market Scenario
			</li>
			<li>
			Present COVID-19 Market Scenario
			</li>
			<li>
			After COVID-19 or Future Scenario
			</li>
		</ol>
		</li>
		<li>
		Pricing Dynamics Amid Covid-19
		</li>
		<li>
		Demand-Supply Spectrum
		</li>
		<li>
		Government Initiatives Related to the Market During Pandemic
		</li>
		<li>
		Manufacturers Strategic Initiatives
		</li>
		<li>
		Conclusion&nbsp;
		</li>
	</ol>
	</li>
	<li>
	By Disease Type

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type Segment
		</li>
		<li>
		Market Attractiveness Index, By Disease Type Segment

		<ol>
			<li>
			Bacterial Skin Infections*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Foodborne Bacterial Infections
			</li>
			<li>
			Sexually Transmitted Bacterial Infections
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	By Therapeutics

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
		</li>
		<li>
		Market Attractiveness Index, By Therapeutics Segment

		<ol>
			<li>
			Beta-Lactam*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Quinolones
			</li>
			<li>
			Macrolides
			</li>
			<li>
			Tetracyclines
			</li>
			<li>
			Sulfonamide
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	By Route of Administration

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
		</li>
		<li>
		Market Attractiveness Index, By Route of Administration Segment

		<ol>
			<li>
			Oral*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Topical
			</li>
			<li>
			Parenteral
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	By Distribution Channel

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
		</li>
		<li>
		Market Attractiveness Index, By Distribution Channel Segment

		<ol>
			<li>
			Hospitals Pharmacies*

			<ol>
				<li>
				Introduction
				</li>
				<li>
				Market Size Analysis, and Y-o-Y Growth Analysis (%)
				</li>
			</ol>
			</li>
			<li>
			Retail Pharmacies
			</li>
			<li>
			Online Pharmacies
			</li>
			<li>
			Others
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	By Region

	<ol>
		<li>
		Introduction
		</li>
		<li>
		Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
		</li>
		<li>
		Market Attractiveness Index, By Region
		</li>
		<li>
		North America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				U.S.
				</li>
				<li>
				Canada
				</li>
				<li>
				Mexico
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Europe

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Germany
				</li>
				<li>
				U.K.
				</li>
				<li>
				France
				</li>
				<li>
				Italy
				</li>
				<li>
				Spain
				</li>
				<li>
				Rest of Europe
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		South America

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				Brazil
				</li>
				<li>
				Argentina
				</li>
				<li>
				Rest of South America
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Asia Pacific

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

			<ol>
				<li>
				China
				</li>
				<li>
				India
				</li>
				<li>
				Japan
				</li>
				<li>
				Australia
				</li>
				<li>
				Rest of Asia Pacific
				</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>
		Middle East and Africa

		<ol>
			<li>
			Introduction
			</li>
			<li>
			Key Region-Specific Dynamics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
			</li>
			<li>
			Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
			</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	Competitive Landscape

	<ol>
		<li>
		Competitive Scenario
		</li>
		<li>
		Market Positioning/Share Analysis
		</li>
		<li>
		Mergers and Acquisitions Analysis
		</li>
	</ol>
	</li>
	<li>
	Company Profiles

	<ol>
		<li>
		Novartis AG*

		<ol>
			<li>
			Company Overview
			</li>
			<li>
			Product Portfolio and Description
			</li>
			<li>
			Key Highlights
			</li>
			<li>
			Financial Overview
			</li>
		</ol>
		</li>
		<li>
		GlaxoSmithkline plc
		</li>
		<li>
		Pfizer Inc.
		</li>
		<li>
		Merck &amp; Co., Inc.
		</li>
		<li>
		Sanofi
		</li>
		<li>
		Allergan
		</li>
		<li>
		Bayer AG
		</li>
		<li>
		AstraZeneca Plc
		</li>
		<li>
		Bristol-Myers Squibb Company
		</li>
		<li>
		Takeda Pharmaceutical Company Limited
		</li>
		<li>
		Baxter
		</li>
		<li>
		Eli Lilly and Company
		</li>
		<li>
		Johnson and Johnson
		</li>
		<li>
		Insmed, Inc.
		</li>
		<li>
		Otsuka Pharmaceuticals Co., Ltd.
		</li>
		<li>
		Roche Holding AG
		</li>
		<li>
		Forest Laboratories, Inc.
		</li>
		<li>
		Teva Pharmaceuticals Industries Ltd.(LIST NOT EXHAUSTIVE)
		</li>
	</ol>
	</li>
	<li>
	DataM Intelligence

	<ol>
		<li>
		Appendix
		</li>
		<li>
		About Us and Services
		</li>
		<li>
		Contact Us
		</li>
	</ol>
	</li>
</ol>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; FIgures</h2>

List of Tables

Table 1Global Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2021,2025 &amp; 2029 ($ Million) 
Table 2 Global Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2021,2025 &amp; 2029 ($ Million) 
Table 3 Global Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2021,2025 &amp; 2029 ($ Million) 
Table 4 Global Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2021,2025 &amp; 2029 ($ Million) 
Table 5 Global Bacterial Infectious Diseases Therapeutics Market Value, By Regions, 2021,2025 &amp; 2029 ($ Million) 
Table 6 Global Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2021,2025 &amp; 2029 ($ Million) 
Table 7 Global Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 8 Global Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2021,2025 &amp; 2029 ($ Million) 
Table 9 Global Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 10 Global Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2021,2025 &amp; 2029 ($ Million) 
Table 11 Global Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 12 Global Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2021,2025 &amp; 2029 ($ Million) 
Table 13 Global Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 14 Global Bacterial Infectious Diseases Therapeutics Market Value, By Region, 2022-2029 ($ Million) 
Table 15 Global Bacterial Infectious Diseases Therapeutics Market Value, By Region, 2022-2029 ($ Million) 
Table 16 North America Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 17 North America Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 18 North America Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 19 North America Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 20 North America Bacterial Infectious Diseases Therapeutics Market Value, By Country, 2022-2029 ($ Million) 
Table 21 South America Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 22 South America Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 23 South America Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 24 South America Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 25 South America Bacterial Infectious Diseases Therapeutics Market Value, By Country, 2022-2029 ($ Million) 
Table 26&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 27&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 28&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 29&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 30&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, By Country, 2022-2029 ($ Million) 
Table 31&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 32&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 33&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 34&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 35&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, By Country, 2022-2029 ($ Million) 
Table 36&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Value, By Disease Type, 2022-2029 ($ Million) 
Table 37&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Value, By Therapeutics, 2022-2029 ($ Million) 
Table 38&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Value, By Route of Administration, 2022-2029 ($ Million) 
Table 39&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Value, By Distribution Channel, 2022-2029 ($ Million) 
Table 40&nbsp;&nbsp; &nbsp;Novartis AG: Overview 
Table 41&nbsp;&nbsp; &nbsp;Novartis AG: Product Portfolio 
Table 42&nbsp;&nbsp; &nbsp;Novartis AG: Key Developments 
Table 43&nbsp;&nbsp; &nbsp;GlaxoSmithkline Plc: Overview 
Table 44&nbsp;&nbsp; &nbsp;GlaxoSmithkline Plc: Product Portfolio 
Table 45&nbsp;&nbsp; &nbsp;GlaxoSmithkline Plc: Key Developments 
Table 46&nbsp;&nbsp; &nbsp;Pfizer Inc.: Overview 
Table 47&nbsp;&nbsp; &nbsp;Pfizer Inc.: Product Portfolio 
Table 48&nbsp;&nbsp; &nbsp;Pfizer Inc.: Key Developments 
Table 49&nbsp;&nbsp; &nbsp;Merck &amp; Co., Inc.: Overview 
Table 50&nbsp;&nbsp; &nbsp;Merck &amp; Co., Inc.: Product Portfolio 
Table 51&nbsp;&nbsp; &nbsp;Merck &amp; Co., Inc.: Key Developments 
Table 52&nbsp;&nbsp; &nbsp;Sanofi: Overview 
Table 53&nbsp;&nbsp; &nbsp;Sanofi: Product Portfolio 
Table 54&nbsp;&nbsp; &nbsp;Sanofi: Key Developments 
Table 55&nbsp;&nbsp; &nbsp;Allergan: Overview 
Table 56&nbsp;&nbsp; &nbsp;Allergan: Product Portfolio 
Table 57&nbsp;&nbsp; &nbsp;Allergan: Key Developments 
Table 58&nbsp;&nbsp; &nbsp;Bayer AG: Overview 
Table 59&nbsp;&nbsp; &nbsp;Bayer AG: Product Portfolio 
Table 60&nbsp;&nbsp; &nbsp;Bayer AG: Key Developments 
Table 61&nbsp;&nbsp; &nbsp;AstraZeneca Plc: Overview 
Table 62&nbsp;&nbsp; &nbsp;AstraZeneca Plc: Product Portfolio 
Table 63&nbsp;&nbsp; &nbsp;AstraZeneca Plc: Key Developments 
Table 64&nbsp;&nbsp; &nbsp;Bristol-Myers Squibb Company: Overview 
Table 65&nbsp;&nbsp; &nbsp;Bristol-Myers Squibb Company: Product Portfolio 
Table 66&nbsp;&nbsp; &nbsp;Bristol-Myers Squibb Company: Key Developments 
Table 67&nbsp;&nbsp; &nbsp;Takeda Pharmaceutical Company Limited: Overview 
Table 68&nbsp;&nbsp; &nbsp;Takeda Pharmaceutical Company Limited: Product Portfolio 
Table 69&nbsp;&nbsp; &nbsp;Takeda Pharmaceutical Company Limited: Key Developments 
Table 70&nbsp;&nbsp; &nbsp;Baxter: Overview 
Table 71&nbsp;&nbsp; &nbsp;Baxter: Product Portfolio 
Table 72&nbsp;&nbsp; &nbsp;Baxter: Key Developments 
Table 73&nbsp;&nbsp; &nbsp;Eli Lilly and Company: Overview 
Table 74&nbsp;&nbsp; &nbsp;Eli Lilly and Company: Product Portfolio 
Table 75&nbsp;&nbsp; &nbsp;Eli Lilly and Company: Key Developments 
Table 76&nbsp;&nbsp; &nbsp;Johnson and Johnson: Overview 
Table 77&nbsp;&nbsp; &nbsp;Johnson and Johnson: Product Portfolio 
Table 78&nbsp;&nbsp; &nbsp;Johnson and Johnson: Key Developments 
Table 79&nbsp;&nbsp; &nbsp;Insmed, Inc.: Overview 
Table 60&nbsp;&nbsp; &nbsp;Insmed, Inc.: Product Portfolio 
Table 61&nbsp;&nbsp; &nbsp;Insmed, Inc.: Key Developments 
Table 62&nbsp;&nbsp; &nbsp;Otsuka Pharmaceuticals Co., Ltd.: Overview 
Table 63&nbsp;&nbsp; &nbsp;Otsuka Pharmaceuticals Co., Ltd.: Product Portfolio 
Table 64&nbsp;&nbsp; &nbsp;Otsuka Pharmaceuticals Co., Ltd.: Key Developments 
Table 65&nbsp;&nbsp; &nbsp;Roche Holding AG: Overview 
Table 66&nbsp;&nbsp; &nbsp;Roche Holding AG: Product Portfolio 
Table 67&nbsp;&nbsp; &nbsp;Roche Holding AG: Key Developments 
Table 68&nbsp;&nbsp; &nbsp;Forest Laboratories, Inc.: Overview 
Table 69&nbsp;&nbsp; &nbsp;Forest Laboratories, Inc.: Product Portfolio 
Table 70&nbsp;&nbsp; &nbsp;Forest Laboratories, Inc.: Key Developments 
Table 71&nbsp;&nbsp; &nbsp;Teva Pharmaceuticals Industries Ltd.: Overview 
Table 72&nbsp;&nbsp; &nbsp;Teva Pharmaceuticals Industries Ltd.: Product Portfolio 
Table 73&nbsp;&nbsp; &nbsp;Teva Pharmaceuticals Industries Ltd.: Key Developments

List of Figures

Figure 1&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 2&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 3&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 4&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 5&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Share, By Region, 2021 &amp; 2029 (%) 
Figure 6&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 7&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Y-o-Y Growth, By Disease Type, 2021-2029 (%) 
Figure 8&nbsp;&nbsp; &nbsp;Bacterial Skin Infections: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 9&nbsp;&nbsp; &nbsp;Foodborne Bacterial Infections: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 10&nbsp;&nbsp; &nbsp;Sexually Transmitted Bacterial Infections: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 11&nbsp;&nbsp; &nbsp;Others: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 12&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Y-o-Y Growth, By Therapeutics, 2021-2029 (%) 
Figure 13&nbsp;&nbsp; &nbsp;Beta-Lactam: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 14&nbsp;&nbsp; &nbsp;Quinolones: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 15&nbsp;&nbsp; &nbsp;Macrolides: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 16&nbsp;&nbsp; &nbsp;Tetracyclines: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 17&nbsp;&nbsp; &nbsp;Others: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 18&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Y-o-Y Growth, By Route of Administration, 2021-2029 (%) 
Figure 19&nbsp;&nbsp; &nbsp;Oral: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 20&nbsp;&nbsp; &nbsp;Topical: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 21&nbsp;&nbsp; &nbsp;Parenteral: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 22&nbsp;&nbsp; &nbsp;Others: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 23&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Y-o-Y Growth, By Distribution Channel, 2021-2029 (%) 
Figure 24&nbsp;&nbsp; &nbsp;Hospitals Pharmacies: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 25&nbsp;&nbsp; &nbsp;Retail Pharmacies: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 26&nbsp;&nbsp; &nbsp;Online Pharmacies: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 27&nbsp;&nbsp; &nbsp;Others: Global Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 28&nbsp;&nbsp; &nbsp;Global Bacterial Infectious Diseases Therapeutics Market Y-o-Y Growth, By Region, 2021-2029 (%) 
Figure 29&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 30&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 31&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 32&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 33&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 34&nbsp;&nbsp; &nbsp;North America Bacterial Infectious Diseases Therapeutics Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 35&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 36&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 37&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 38&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 39&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 40&nbsp;&nbsp; &nbsp;South America Bacterial Infectious Diseases Therapeutics Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 41&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 42&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 43&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 44&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 45&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 46&nbsp;&nbsp; &nbsp;Europe Bacterial Infectious Diseases Therapeutics Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 47&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 48&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 49&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 50&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 51&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 52&nbsp;&nbsp; &nbsp;Asia-Pacific Bacterial Infectious Diseases Therapeutics Market Share, By Country, 2021 &amp; 2029 (%) 
Figure 53&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Value, 2022-2029 ($ Million) 
Figure 54&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Share, By Disease Type, 2021 &amp; 2029 (%) 
Figure 55&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Share, By Therapeutics, 2021 &amp; 2029 (%) 
Figure 56&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Share, By Route of Administration, 2021 &amp; 2029 (%) 
Figure 57&nbsp;&nbsp; &nbsp;Middle East &amp; Africa Bacterial Infectious Diseases Therapeutics Market Share, By Distribution Channel, 2021 &amp; 2029 (%) 
Figure 58&nbsp;&nbsp; &nbsp;Novartis AG: Financials 
Figure 59&nbsp;&nbsp; &nbsp;GlaxoSmithkline Plc: Financials 
Figure 60&nbsp;&nbsp; &nbsp;Pfizer Inc.: Financials 
Figure 61&nbsp;&nbsp; &nbsp;Merck &amp; Co., Inc.: Financials 
Figure 62&nbsp;&nbsp; &nbsp;Sanofi: Financials 
Figure 63&nbsp;&nbsp; &nbsp;Allergan: Financials 
Figure 64&nbsp;&nbsp; &nbsp;Bayer AG: Financials 
Figure 65&nbsp;&nbsp; &nbsp;AstraZeneca Plc: Financials 
Figure 66&nbsp;&nbsp; &nbsp;Bristol-Myers Squibb Company: Financials 
Figure 67&nbsp;&nbsp; &nbsp;Takeda Pharmaceutical Company Limited: Financials 
Figure 68&nbsp;&nbsp; &nbsp;Baxter: Financials 
Figure 69&nbsp;&nbsp; &nbsp;Eli Lilly and Company: Financials 
Figure 70&nbsp;&nbsp; &nbsp;Johnson and Johnson: Financials 
Figure 71&nbsp;&nbsp; &nbsp;Insmed, Inc.: Financials 
Figure 72&nbsp;&nbsp; &nbsp;Otsuka Pharmaceuticals Co., Ltd.: Financials 
Figure 73&nbsp;&nbsp; &nbsp;Roche Holding AG: Financials 
Figure 74&nbsp;&nbsp; &nbsp;Forest Laboratories, Inc.: Financials 
Figure 75&nbsp;&nbsp; &nbsp;Teva Pharmaceuticals Industries Ltd.: Financials